Real-World Study Reports PFS and OS in Metastatic CRC

Share this content:
A Merck-funded study examines survival data on patients with metastatic colorectal cancer; results were presented during ESMO 2018.
A Merck-funded study examines survival data on patients with metastatic colorectal cancer; results were presented during ESMO 2018.
The following article features coverage from the ESMO World Congress on Gastrointestinal Cancer 2018 meeting. Click here to read more of Cancer Therapy Advisor's conference coverage.

Real-world data indicate that the median progression-free (PFS) survival of patients with metastatic colorectal cancer (mCRC) was 9.6 months after first-line chemotherapy, with a median overall survival (OS) ranging from 18 to 25.2 months, according to a study presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2018.1

Given that clinical trials do not necessarily represent populations treated in the clinic, this study aimed to determine the outcomes of patients with mCRC in the real world.

The RWD-ACROSS cohort study included 804 adult patients from 4 hospitals in Spain with mCRC diagnosed between 2011 and 2015. The median age at diagnosis was 65.7 and 64.9% of patients were male. Mutations in RAS were harbored by 50.1% of tumors, BRAF mutations by 1.6%, and microsatellite instability by 3.4%. The tumors were synchronous or metachronous in 5.7% of cases, and 73.4% were on the left side. The most common location of metastasis was the liver, followed by the peritoneum and lung.

In the study, 63.8% of patients received 2 lines of therapy, 28.5% received 3 lines, and 9.1% were treated with 4 or more lines of therapy. First-line treatment was most commonly chemotherapy alone (51.6%) or chemotherapy combined with an anti-EGFR or anti-VEGF antibody (48.4%). The results were similar for second-line therapy.

The median PFS with first-, second-, and third-line treatment was 9.6, 7.6, and 6.7 months, respectively. OS varied according to the location of the tumor, with left-sided tumors associated with a longer median OS of 25.2 months compared with 18 months for right-sided tumors (hazard ratio, 0.63; P < .001). The 12-, 24-, 36-, and 48-month OS was 73.3%, 48.2%, 30.7%, and 21.1%, respectively.

The authors noted that this was the first database study to report data on “CT, biologics, OS, PFS, and prognostic and predictive factors.”

Read more of Cancer Therapy Advisor's coverage of the ESMO World Congress on Gastrointestinal Cancer 2018 meeting by visiting the conference page.

Reference

  1. Pericay C, Gallego J, Fernandez Montes A, et al. Real world data in colorectal cancer: A retrospective analysis of overall survival in metastatic colorectal cancer patients between 2011-2015 treated in Spain, preliminary results (RWD-ACROSS study). Ann Oncol. 2018;29 (suppl 5;abstr P-277):v78. doi:10.1093/annonc/mdy151.276

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs